Mirador Capital Partners LP Decreases Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mirador Capital Partners LP lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.0% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,238 shares of the medical research company’s stock after selling 347 shares during the quarter. Thermo Fisher Scientific makes up about 0.9% of Mirador Capital Partners LP’s holdings, making the stock its 26th largest holding. Mirador Capital Partners LP’s holdings in Thermo Fisher Scientific were worth $4,788,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in TMO. Gotham Asset Management LLC raised its holdings in Thermo Fisher Scientific by 47.5% in the 3rd quarter. Gotham Asset Management LLC now owns 2,654 shares of the medical research company’s stock valued at $1,343,000 after acquiring an additional 855 shares during the last quarter. Schonfeld Strategic Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 54.3% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 12,107 shares of the medical research company’s stock worth $6,128,000 after acquiring an additional 4,260 shares during the period. Waverly Advisors LLC grew its holdings in shares of Thermo Fisher Scientific by 6.2% in the third quarter. Waverly Advisors LLC now owns 2,233 shares of the medical research company’s stock valued at $1,130,000 after purchasing an additional 131 shares during the period. United Services Automobile Association acquired a new stake in Thermo Fisher Scientific during the third quarter worth about $5,300,000. Finally, First Business Financial Services Inc. acquired a new position in Thermo Fisher Scientific in the 3rd quarter valued at about $210,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.1 %

Shares of TMO traded up $0.77 during mid-day trading on Monday, reaching $553.77. The company’s stock had a trading volume of 45,554 shares, compared to its average volume of 1,539,744. The company’s 50 day moving average is $574.84 and its 200 day moving average is $563.36. The stock has a market cap of $211.39 billion, a PE ratio of 35.47, a price-to-earnings-growth ratio of 2.58 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 12-month low of $415.60 and a 12-month high of $603.82. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.33.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, April 24th. The medical research company reported $5.11 earnings per share for the quarter, topping analysts’ consensus estimates of $4.70 by $0.41. The company had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.65 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Investors of record on Friday, June 14th will be given a $0.39 dividend. The ex-dividend date of this dividend is Friday, June 14th. This represents a $1.56 annualized dividend and a yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.01%.

Wall Street Analyst Weigh In

Several analysts have recently commented on TMO shares. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target on the stock. Barclays decreased their price target on Thermo Fisher Scientific from $615.00 to $600.00 and set an “equal weight” rating on the stock in a research note on Friday. JPMorgan Chase & Co. upped their target price on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research report on Thursday, April 25th. HSBC boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a research note on Tuesday, April 30th. Finally, Evercore ISI lifted their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Five investment analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $607.06.

Insiders Place Their Bets

In related news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the transaction, the chief executive officer now owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $572.41, for a total transaction of $5,724,100.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $70,873,516.56. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Michael A. Boxer sold 2,000 shares of the firm’s stock in a transaction on Friday, April 26th. The stock was sold at an average price of $567.94, for a total transaction of $1,135,880.00. Following the completion of the sale, the senior vice president now owns 13,083 shares of the company’s stock, valued at approximately $7,430,359.02. The disclosure for this sale can be found here. In the last three months, insiders have sold 22,000 shares of company stock valued at $12,532,780. Insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.